ALPN Alpine Immune Sciences Inc.

3.05
+0.3  (+11%)
Previous Close 2.75
Open 2.87
Price To Book 1.25
Market Cap 56,692,314
Shares 18,587,644
Volume 22,332
Short Ratio
Av. Daily Volume 25,331
Stock charts supplied by TradingView

NewsSee all news

  1. Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2019 Financial Results

    Company Advancing ALPN-101 into a Phase 1/2 Acute Graft versus Host Disease Study (BALANCE) Phase 1 Study (NEON-1) of Lead Oncology Program ALPN-202 Planned to Commence in Q1 2020 Conference Call Scheduled for 4:30

  2. Alpine Immune Sciences Presents New ALPN-101 Preclinical Data at the 2019 American College of Rheumatology (ACR) Annual Meeting

    ALPN-101 is distinct from the other biologic therapies and superior to combination biological blockade Preclinical activity suggests unique effectiveness across a range of rheumatic and other inflammatory

  3. Alpine Immune Sciences Presents New Preclinical Data at The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

     Preclinical data support unique mechanism of action of ALPN-202 as a first in class conditional CD28 Agonist ALPN-202 able to increase CD8+ T-cells in tumors ALPN-202 has potent monotherapy activity and

  4. Alpine Immune Sciences Announces Oral Presentation of ALPN-101 at the 61st American Society of Hematology Annual Meeting and Exposition

    Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced an abstract

  5. Alpine Immune Sciences Completes Enrollment of Phase I Study of ALPN-101 and Announces Third Quarter Conference Call

    Company to Discuss Topline Results and Provide Company Update on Third Quarter 2019 Conference Call and Webcast Scheduled for November 13, 2019 at 4:30 p.m. ET Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data released February 24, 2017 - primary endpoint not met.
N91115
Cystic Fibrosis - one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein
Phase 1 presentation at ASH December 8, 2019: 11:00 AM ET.
ALPN-101
Healthy volunteers
Phase 1 trial to be initiated 1Q 2020.
ALPN-202
Advanced Malignancies

Latest News

  1. Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2019 Financial Results

    Company Advancing ALPN-101 into a Phase 1/2 Acute Graft versus Host Disease Study (BALANCE) Phase 1 Study (NEON-1) of Lead Oncology Program ALPN-202 Planned to Commence in Q1 2020 Conference Call Scheduled for 4:30

  2. Alpine Immune Sciences Presents New ALPN-101 Preclinical Data at the 2019 American College of Rheumatology (ACR) Annual Meeting

    ALPN-101 is distinct from the other biologic therapies and superior to combination biological blockade Preclinical activity suggests unique effectiveness across a range of rheumatic and other inflammatory

  3. Alpine Immune Sciences Presents New Preclinical Data at The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

     Preclinical data support unique mechanism of action of ALPN-202 as a first in class conditional CD28 Agonist ALPN-202 able to increase CD8+ T-cells in tumors ALPN-202 has potent monotherapy activity and

  4. Alpine Immune Sciences Announces Oral Presentation of ALPN-101 at the 61st American Society of Hematology Annual Meeting and Exposition

    Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced an abstract

  5. Alpine Immune Sciences Completes Enrollment of Phase I Study of ALPN-101 and Announces Third Quarter Conference Call

    Company to Discuss Topline Results and Provide Company Update on Third Quarter 2019 Conference Call and Webcast Scheduled for November 13, 2019 at 4:30 p.m. ET Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a

  6. Alpine Immune Sciences Announces Upcoming Scientific Presentations at SITC and ACR/ARHP 2019 Annual Meetings

    Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced planned

  7. Alpine Immune Sciences to Present at 2019 Ladenburg Thalmann Healthcare Conference

    Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company